Activators of CXCR3 for the treatment of angiopathies of the eye
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsAlan H. Wells, Cecelia C. Yates-Binder, Joel S. Schuman
Life of this patent
Estimating the term…
Abstract
The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of C-X-C chemokine receptor 3 (CXCR3). In some embodiments, the activator of CXCR3 is interferon-γ-inducible 10 kDa protein (IP-10) or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal α-helix of IP-10. In other embodiments, the activator of CXCR3 is platelet factor 4 (PF4) or a fragment or variant thereof.
Claims7
A method of treating an angiogenic disorder of the eye, or treating aberrant angiogenesis of the eye in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an activator of C-X-C chemokine receptor 3 (CXCR3), wherein the CXCR3 activator is a biologically active interferon-γ-inducible 10 kDa protein (IP-10) peptide fragment consisting of SEQ ID NO:
- 6, thereby treating the angiogenic disorder, or treating the aberrant angiogenesis.
Dependencies are inferred from the claim text.